Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||LOXO-305 + Rituximab + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LOXO-305||LOXO 305|LOXO305|pirtobrutinib||BTK inhibitor 28||LOXO-305 selectively inhibits activation of BTK, which results in decreased tumor growth (PMID: 32170458, PMID: 33676628).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 14||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 23||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03740529||Phase Ib/II||Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305||A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL||Recruiting||USA | ITA | FRA||7|
|NCT04965493||Phase III||Rituximab + Venetoclax LOXO-305 + Rituximab + Venetoclax||A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)||Recruiting||USA | ITA | FRA | ESP | BEL||11|